{"schema_version":"secwatch.filing_event.v1","accession":"0001937653-25-000026","form_type":"8-K","ticker":"ZYME","cik":"0001937653","company_name":"Zymeworks Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.509168+00:00","generated_at":"2026-05-22T05:43:14.266406+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Zymeworks Q1 revenue $27.1M, net loss narrows to $22.6M; cash runway into 2H-2027","bullets":["Revenue of $27.1M (vs. $10.0M in Q1 2024); net loss of $22.6M improved from $31.7M.","Cash resources $321.6M; combined with anticipated milestones expected to fund operations into 2H-2027.","Partner Jazz received EMA positive opinion for zanidatamab in HER2+ BTC; final decision pending.","Recognized $14.0M GSK milestone (paid Apr 2025) and $3.1M Daiichi Sankyo milestone; additional milestones remain.","Appointed Dr. Sabeen Mekan as SVP Clinical Development; six preclinical posters presented at AACR."],"urls":{"canonical":"https://secwatch.observer/filing/0001937653-25-000026","json":"https://secwatch.observer/filing/0001937653-25-000026.json","markdown":"https://secwatch.observer/filing/0001937653-25-000026.md","text":"https://secwatch.observer/filing/0001937653-25-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937653/000193765325000026/0001937653-25-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937653/000193765325000026/zyme-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:43:14.266406+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}